ADC Therapeutics SA

World Rank (Jan-05-2024)

19,359

Market Cap (Jan-05-2024)

0.152 Billion USD

World Rank (Jul-30-2023)

21,504

Market Cap (Jul-30-2023)

0.103 Billion USD

World Rank (Jan-07-2022)

7,370

Market Cap (Jan-07-2022)

1.519 Billion USD

World Rank (Jan-01-2021)

4,862

Market Cap (Jan-01-2021)

2.456 Billion USD

Headquarters Country

Switzerland

Nasdaq / NYSE Code

ADCT

Market Cap (Mar-08-2026)

0.51

Employee Count

116

Employee Count as of Date

As on 2020

World Region

Europe

World Subregion

Western Europe

Annual Revenue in USD

0 Million USD

Annual Net Income in USD

-246 Million USD

Annual Results for Period Ending

Dec-2020 ending year

Balance Sheet for Period Ending

Dec-2020 ending year

Business Sector

Company Website

Yahoo

Company Profile

ADC Therapeutics is a Clinical Stage Oncology Biotechnology company, development and commercialization of next generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology. The headquarters is in Switzerland.

Facts About Company

ADC Therapeutics company annual revenue was 209 million USD and annual net loss was -155 million USD as on Dec-2022.

IPO Year

2020

Stock Exchange

NYSE

Nasdaq Sector

Health Care

Nasdaq Industry

Biotechnology: Pharmaceutical Preparations